Last updated on February 2017

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma


Brief description of study

This first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced adrenocortical carcinoma whose tumor has progressed on standard therapy. Information will also be collected to determine how long ATR-101 stays in the blood, and if any effect on tumor progression is seen. Biomarkers (blood and urine tests) will determine if any effects on production of steroid hormones (cortisol, aldosterone, estrogen and testosterone) are seen.

Clinical Study Identifier: NCT01898715

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jeffery Russell, MD, PhD

Moffitt Cancer Center
Tampa, FL United States
  Connect »

Electron Kebebew, MD

National Institutes of Health/National Cancer Institute
Bethesda, MD United States
  Connect »

David C. Smith, MD

University of Michigan Cancer Center
Ann Arbor, MI United States
  Connect »

Aung Naing, MD

MDAnderson Cancer Center
Houston, TX United States
  Connect »

Martin Fassnacht, MD

Comprehensive Cancer Center Mainfranken, University Hospital of W rzburg
Würzburg, Germany
  Connect »